David A. Siegel Caladrius Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.74 $28,208 - $50,912	-68,800 Reduced 50.0%	68,800 $36,000
Q1 2022 May 16, 2022	SELL	$0.63 - $1.03 $62,874 - $102,794	-99,800 Reduced 42.04%	137,600 $99,000
Q4 2021 Feb 14, 2022	BUY	$0.83 - $1.22 $197,042 - $289,628	237,400 New	237,400 $200,000
Q2 2021 Aug 16, 2021	SELL	$1.4 - $1.9 $19,040 - $25,840	-13,600 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.44 - $2.89 $77,760 - $156,060	-54,000 Reduced 79.88%	13,600 $26,000
Q4 2020 Feb 16, 2021	BUY	$1.39 - $1.87 $93,964 - $126,412	67,600 New	67,600 $97,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.